drugset / Trial / NCT04974151

Summary

This is a multi-center, randomized, double-blind, triple-dummy, controlled trial in 24,000 Chinese men and women with hypertension and MTHFR 677 TT genotype. The study participants will be randomized to one of the three treatment groups: Group A: amlodipine tablet (5mg), taken orally, once daily, serving as active comparator. Group B: amlodipine folic acid 5.8mg tablet (5mg amlodipine and 0.8mg folic acid), taken orally, once daily. Group C: amlodipine folic acid 5.8mg tablet plus 5-methyltetrahydrofolate (5-MTHF, 0.4mg), taken orally, once daily. The primary endpoint is first ischemic stroke.

Timeline

Start
2024-08-22
Primary completion
2029-06-30
Completion
2029-06-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject 5-MTHF Unknown 0.4 mg Oral
Subject Amlodipine Other / unclassified 5 mg Oral
Subject Amlodipine besylate And Folic Acid Unknown 5.8 mg Oral